May 2012 Issue
Perfecting the timing and precision of the moisturizing and drying procedures can eliminate or at least drastically reduce coating problems.
In the case of disposable cleanroom apparel the benefits can include an easier gowning process, elimination of variability in filtration performance that can result from reusing apparel, less waste and improved levels of contamination control.
The company aims to leverage the expertise it has always had in-house, yet hadnt fully capitalized on with the pharma industry, says VP Christophe Couturier.
This years PDA Annual Conference paid special attention to the issues posed by use of single-use biopharmaceutical processing equipment.
Solution providers churn out new and improved products in the heated market for upstream and downstream filtration technology.
Consultant Robert Dream shares thoughts on evolving industries
Are you using statistics to support the status quo, or to get to true root cause?
Salary does not dictate motivation and performance.
An interview with Thomas Schilling on the companys Green IT initiative.
A talk with sustainability manager Johanna Jobin about the company's new product recycling initiative.
Drug industry environmental stewardship projects are becoming more sophisticated and challenging. Here are examples from AstraZeneca, Bayer, DSM, Pfizer, and EMD Millipore
Pharmaceutical plant managers are taking a more sophisticated approach when it comes to energy management by examining everything from alternative fuel and energy supply options to demand response, reliability, and on-site generation.
A Framework for Technology Transfer to Satisfy the Requirements of the New Process Validation Guidance: Part 2
In the life of any drug product, the technology transfer of a process is a complex matter, made more complicated by the new definition of the Process Validation (PV) guidance issued by FDA in January 2011.
New technologies are finding far more organisms than before, creating the need for a rational, comprehensive approach to environmental monitoring.
How do we measure the impact of social media? Its a question being addressed by most drug companies, who have their own theories and formulas.
Regulatory compliance should be the byproduct, not the goal.